XVIVO Perfusion published prospectus regarding the public offer to the holders of shares and warrants of series 2015/2016 in Vivoline Medical

The prospectus[1] regarding XVIVO Perfusion AB’s (publ) (”XVIVO Perfusion”)
recommended public offer to the holders of shares (“Shares”) and warrants of
series 2015/2016 (“Warrants”) in Vivoline Medical AB (“Vivoline”) to transfer
all of their Shares and Warrants to XVIVO Perfusion (the “Offer”) has been
approved by the Swedish Financial Supervisory Authority (the “SFSA”) and is now
available on inter alia XVIVO Perfusion’s website.
The Offer is not made, and this press release may not, directly nor indirectly,
be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South
Africa or the U.S or in any other country where making of the Offer,
distribution of this press release or acceptance of the Offer would be contrary
to applicable laws or rules or would require further offering documentation or
registration or any other measures in addition to what is required by Swedish
law.

XVIVO Perfusion announced on 18 April 2016 a recommended public offer to the
holders of Shares and Warrants in Vivoline by a press release. XVIVO Perfusion
offers SEK 1.2921 in cash and 0.1543 shares in XVIVO Perfusion (the “Bidder
Shares”) for every Share and for every Warrant SEK 0.7226 in cash and 0.0863
Bidder Shares are offered.

The Swedish language prospectus regarding the Offer has today been approved and
registered by the SFSA. The prospectus, a blank application form and the
information brochure can be downloaded in an electronic format from XVIVO
Perfusion’s website (www.xvivoperfusion.com) and Pareto Securities’ website
(www.paretosec.com). Holders of Shares or Warrants whose Shares or Warrants are
held with a custodian must contact their custodian in order to obtain further
instructions on how to accept the Offer.

Pre-printed application form, return envelope and information brochure will be
distributed to holders of Shares and Warrants whose Shares or Warrants are
directly registered with Euroclear Sweden AB on the record date 11 May 2016.

Time plan for the Offer

Record date:                            11 May 2016
Acceptance period:                      16 May – 7 June 2016
Payment of the consideration begins:    around 13 June 2016

XVIVO Perfusion reserves the right to extend the acceptance period and to
postpone the date for payment of the consideration. XVIVO Perfusion will
announce such extensions of the acceptance period and/or postponements of the
date for payment of the consideration by press releases in accordance with
applicable laws and regulations.

The information provided herein is such that XVIVO Perfusion is obligated to
disclose pursuant to the Takeover Rules. The information was submitted for
publication at 2.00 p.m. CET, 10 May 2016.

For further information, please contact:

Magnus Nilsson, CEO
+46 (0)31-788 21 50
magnus.nilsson@xvivoperfusion.com

Gothenburg 10 May 2016
XVIVO Perfusion AB (publ)

This is a translation of the Swedish original version of the press release. In
case of any discrepancies, the Swedish wording shall prevail.

IMPORTANT INFORMATION

The Offer, in accordance with the terms stated in this press release, is not
being made to persons whose participation in the Offer requires that any
additional offer document or prospectus is prepared or registration effected or
that any other measures are taken in addition to those required under Swedish
laws and rules.

This press release and any other documentation relating to the Offer are not
being distributed and must not be mailed or otherwise distributed or sent in or
into any country in which distribution or offering would require any such
additional measures to be taken or would be in conflict with any law or
regulation in such country – XVIVO Perfusion will not allow or accept any such
measure. Any purported acceptance of the Offer resulting directly or indirectly
from a violation of these restrictions may be disregarded.

The Offer is not being made and will not be made, directly or indirectly, by use
of mail or any other communication means or facility, either by
intergovernmental nature or for foreign trade or through national stock
exchanges’ facilities, in or into Australia, Hong Kong, Japan, Canada, New
Zealand, South Africa or the U.S. This includes, without limitation, facsimile
transmission, electronic mail, telex, telephone and the internet or other forms
of electronic distribution. The Offer cannot be accepted and Shares and Warrants
cannot be transferred in the Offer, by any such measures, means, instrumentality
or facility of, or from within Australia, Hong Kong, Japan, Canada, New Zealand,
South Africa or the U.S. or by persons that are located in, or resident in
Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.
Accordingly, this press release and any documentation related to the Offer are
not being and should not be mailed or otherwise distributed, forwarded or sent
in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the
U.S. or to a person that is located in, or resident in Australia, Hong Kong,
Japan, Canada, New Zealand, South Africa or the U.S.

Every attempt to transfer Shares or Warrants in the Offer which, directly or
indirectly, is a result of a violation of these restrictions is invalid and
every attempt to transfer Shares or Warrants by a person who is located in
Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S. or by
representatives, agents or other intermediary who acts on non-discretionary
basis for a principal who delivers instructions from or within Australia, Hong
Kong, Japan, Canada, New Zealand, South Africa or the U.S. is invalid and will
not be accepted. Every person who holds Shares or Warrants and who participates
in the Offer will certify that the person is not from, or is not located in or
deliver instructions to participate in the Offer from, Australia, Hong Kong,
Japan, Canada, New Zealand, South Africa or the U.S., and that they are not
acting on a non-discretionary basis on behalf of a principal who is from, is
located in or gives an order to participate in the Offer from Australia, Hong
Kong, Japan, Canada, New Zealand, South Africa or the U.S. XVIVO Perfusion will
not deliver any consideration in accordance with the Offer in or into Australia,
Hong Kong, Japan, Canada, New Zealand, South Africa or the U.S.

This press release is not being, and must not be, sent to holders of Shares or
Warrants with registered addresses in Australia, Hong Kong, Japan, Canada, New
Zealand, South Africa or the U.S. Banks, brokers, dealers and other nominees
holding Shares or Warrants for persons in Australia, Hong Kong, Japan, Canada,
New Zealand, South Africa or the U.S. may not forward this press release or any
other document received in connection with the Offer to such persons.

The term “U.S.” shall in this section have the meaning the United States of
America, its territories and dependencies (including Puerto Rico, American
Virgin Islands, Guam, American Samoa, Wake Islands and Commonwealth of the
Northern Mariana Islands), every state within the United States of America and
the Columbia District.

Forward-looking statements

Statements in this press release relating to future status or circumstances,
including statements regarding future performance, growth and other trend
projections and the other benefits of the Offer, are forward-looking statements.
These statements may generally, but not always, be identified by the use of
words such as “anticipates”, “intends”, “expects”, “believes”, or similar
expressions. By their nature, forward-looking statements involve risk and
uncertainty because they relate to events and depend on circumstances that will
occur in the future. There can be no assurance that actual results will not
differ materially from those expressed or implied by these forward-looking
statements due to many factors, many of which are outside the control of XVIVO
Perfusion. All such forward-looking statements are only valid as of the day when
the statements were made and XVIVO Perfusion does not have any obligations (and
does not undertake any obligation) to update or audit the statements, as a
consequence of new information, future occurrences or other circumstances,
except as required according to law and other regulation.

[1] The prospectus also includes the required information that an offer document
must include pursuant to the Takeover rules for certain trading platforms issued
by the Swedish Corporate Governance Board.
For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com